Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

How TAVR implant depth impacts outcomes | A closer look at GLP-1 drugs & AFib | BATMAN technique to the rescue

News You Need to Know Today
How TAVR implant depth impacts outcomes | A closer look at GLP-1 drugs & AFib | BATMAN technique to the rescue
Tuesday, May 26, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

How TAVR valve implant depth impacts clinical outcomes

TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.

READ MORE >
cardiologists heart doctors
Share on Twitter Share on Facebook Share on Linkedin

How TAVR valve implant depth impacts clinical outcomes

Share on Twitter Share on Facebook Share on Linkedin
cardiologists heart doctors
TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.
READ MORE >

Inflammation may help explain how GLP-1 drugs prevent AFib

Kenneth Bilchick, MD, spoke to Cardiovascular Business about new data he presented at Heart Rhythm 2026. 

READ MORE >
Kenneth Bilchick, MD, MS, Director of Electrophysiology Research, and a professor of cardiovascular medicine at the University of Virginia, explains GLP-1 receptor agonists (GLP-RAs) may do more than drive weight loss—showing a significantly lower risk of atrial fibrillation.
Share on Twitter Share on Facebook Share on Linkedin

Inflammation may help explain how GLP-1 drugs prevent AFib

Share on Twitter Share on Facebook Share on Linkedin
Kenneth Bilchick, MD, MS, Director of Electrophysiology Research, and a professor of cardiovascular medicine at the University of Virginia, explains GLP-1 receptor agonists (GLP-RAs) may do more than drive weight loss—showing a significantly lower risk of atrial fibrillation.
Kenneth Bilchick, MD, spoke to Cardiovascular Business about new data he presented at Heart Rhythm 2026. 
READ MORE >

BATMAN to the rescue: TMVR technique helps cardiologists reduce risk of LVOT obstruction

LVOT obstruction is a serious complication of TMVR. BATMAN may help protect patients from LVOT obstruction without leading to any additional risks.

READ MORE >
How BATMAN technique can reduce risk of LVOT obstruction during TMVR
Share on Twitter Share on Facebook Share on Linkedin

BATMAN to the rescue: TMVR technique helps cardiologists reduce risk of LVOT obstruction

Share on Twitter Share on Facebook Share on Linkedin
How BATMAN technique can reduce risk of LVOT obstruction during TMVR
LVOT obstruction is a serious complication of TMVR. BATMAN may help protect patients from LVOT obstruction without leading to any additional risks.
READ MORE >

Featured Articles

FDA warns public about Johnson & Johnson heart pump controllers after patient death

The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025. 

READ MORE >
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
Share on Twitter Share on Facebook Share on Linkedin

FDA warns public about Johnson & Johnson heart pump controllers after patient death

Share on Twitter Share on Facebook Share on Linkedin
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025. 
READ MORE >

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 
READ MORE >

'Compelling' study shows promise of new pulmonary embolectomy system

"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained. 

READ MORE >
Jupiter Endovascular's Vertex Pulmonary Embolectomy System showed positive results in its SPIRARE II pivotal trial.
Share on Twitter Share on Facebook Share on Linkedin

'Compelling' study shows promise of new pulmonary embolectomy system

Share on Twitter Share on Facebook Share on Linkedin
Jupiter Endovascular's Vertex Pulmonary Embolectomy System showed positive results in its SPIRARE II pivotal trial.
"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained. 
READ MORE >

Medtronic recalls thousands of surgical devices due to contamination risk

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

READ MORE >
warning safety alert recall healthcare issue
Share on Twitter Share on Facebook Share on Linkedin

Medtronic recalls thousands of surgical devices due to contamination risk

Share on Twitter Share on Facebook Share on Linkedin
warning safety alert recall healthcare issue
This Class II recall includes more than 18,000 cannulae used during cardiac surgery.
READ MORE >

In Case You Missed It

Stroke prevention devices for TAVR fail to make an impact

Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.

READ MORE >
Stroke - head with text
Share on Twitter Share on Facebook Share on Linkedin

Stroke prevention devices for TAVR fail to make an impact

Share on Twitter Share on Facebook Share on Linkedin
Stroke - head with text
Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.
READ MORE >

Surgery still outperforms GLP-1 drugs in terms of heart health

Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.

READ MORE >
doctor with overweight patient who may be treated with TAVR or surgery
Share on Twitter Share on Facebook Share on Linkedin

Surgery still outperforms GLP-1 drugs in terms of heart health

Share on Twitter Share on Facebook Share on Linkedin
doctor with overweight patient who may be treated with TAVR or surgery
Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.
READ MORE >

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

READ MORE >
cardiologists evaluating the human heart to provide a treatment strategy
Share on Twitter Share on Facebook Share on Linkedin

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

Share on Twitter Share on Facebook Share on Linkedin
cardiologists evaluating the human heart to provide a treatment strategy
When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 
READ MORE >

In Other News

Physical therapist sentenced in $11M Amtrak conspiracy, one of 19 to plead guilty

The U.S. Department of Justice says its investigation into the scheme to defraud Amtrak’s employee health plan resulted in 19 prosecutions, all resulting in guilty pleas. For her role in over $2.2M of fraudulent billing, physical therapist Taejin Kim will serve a year in prison.

READ MORE >
Amtrak eastbound Southwest Chief about to pass under Route 66
Share on Twitter Share on Facebook Share on Linkedin

Physical therapist sentenced in $11M Amtrak conspiracy, one of 19 to plead guilty

Share on Twitter Share on Facebook Share on Linkedin
Amtrak eastbound Southwest Chief about to pass under Route 66
The U.S. Department of Justice says its investigation into the scheme to defraud Amtrak’s employee health plan resulted in 19 prosecutions, all resulting in guilty pleas. For her role in over $2.2M of fraudulent billing, physical therapist Taejin Kim will serve a year in prison.
READ MORE >

Long COVID resurfaces in the national dialogue after long absence from the headlines

In early 2025 public health researchers at City University of New York projected Long COVID would cost the U.S. $6.6 billion over three years. This week two members of that research team amplified their findings and updated their projections.

READ MORE >
sick in bed
Share on Twitter Share on Facebook Share on Linkedin

Long COVID resurfaces in the national dialogue after long absence from the headlines

Share on Twitter Share on Facebook Share on Linkedin
sick in bed
In early 2025 public health researchers at City University of New York projected Long COVID would cost the U.S. $6.6 billion over three years. This week two members of that research team amplified their findings and updated their projections.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Shockwave Medical's new IVL catheter | BATMAN to the rescue | Antiplatelet drugs after PCI | FDA announces recalls
When TAVR patients require surgery later in life | Colleagues pay tribute to a cardiology powerhouse | Much more
TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT
Recall announced after 3 injuries | Medical societies respond to government report | New-look pacemaker requires no implant
Is coffee bad for the heart? | FDA approves new hypertension drug | Stolen devices sold to patients | BP drug recalled
OIG questions vascular procedures | Things to consider before signing your next contract | Is coffee bad for the heart?
Looking Back: Cardiovascular care hit by major recalls | New payment model on the way | SMART update | Trends in cardiac CT

Pagination

    • First page « First
    • Previous page ‹‹
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup